1. Short title This Act may be cited as the Menopause Research and Equity Act of 2023 . 2. Evaluation of completed and ongoing research related to menopause, perimenopause, or mid-life women’s health (a) In general The Director of the National Institutes of Health shall— (1) conduct an evaluation of— (A) the results of research related to menopause, perimenopause, or mid-life women’s health that is complete; (B) the status of such research that is ongoing; and (C) any gaps in knowledge and research on— (i) treatments for menopause-related symptoms; and (ii) the safety and effectiveness of treatments for menopause-related symptoms; and (2) as part of such evaluation, identify the total amount of funding allocated by the National Institutes of Health for the conduct or support of research related to menopause, perimenopause, or mid-life women’s health over the preceding 5 fiscal years. (b) Report; strategic plan Not later than 180 days after the date of enactment of this Act, the Director of the National Institutes of Health shall submit to the Congress— (1) a plan to perform the evaluation under subsection (a); and (2) a plan to develop a strategy, based on such evaluation, that will— (A) be designed and implemented by the Director in cooperation with a multidisciplinary group of health professionals including gynecologists, oncologists, endocrinologists, cardiologists, and neuroscientists; (B) include strategies to resolve the gaps in knowledge and research identified in the report